-
Importation of MSD's Molnupiravir Capsules approved with condition
2022-12-30
The importation registration of Molnupiravir Capsules (trade name: 利卓瑞/LAGEVRIO) for the treatment of COVID-19 of MSD Inc. is approved with condition for marketing by China NMPA on December 29, through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
-
Provisions for Supervision and Administration of Online Drug Sales
2022-12-29
The Provisions for Supervision and Administration of Online Drug Sales is promulgated by Decree No. 58 of the State Administration for Market Regulation on August 3, 2022 and shall be effective as of December 1, 2022.
-
NMPA delegate elected co-chair of GHWP’s Technical Committee
2023-02-17
The meeting elected the technical committee office and the chairs and co-chairs of all working groups for the new term. Delegates of the NMPA participated in the election of the co-chair of the Technical Committee and chairs of Working Group 7 and Working Group 9.
-
Xu Jinghe elected chairman of GHWP
2023-02-17
On Feb 16, Xu Jinghe, deputy commissioner of China's National Medical Products Administration, was elected chairman of the 27th Global Harmonization Working Party in Riyadh, capital of Saudi Arabia.
-
Protein-based booster shots help fight Omicron
2023-02-17
China has recently rolled out two protein-based COVID-19 vaccines to serve as booster shots against Omicron subvariants, bringing new weapons to China's fight against mutated strains of the virus.
-
Xu Jinghe meets with CEO of Saudi Food and Drug Authority
2023-02-16
Xu Jinghe, deputy commissioner of China's National Medical Products Administration, held talks with Hisham bin Saad Aljadhey, CEO of the Saudi Food and Drug Authority, on Feb 16 in Riyadh, capital of Saudi Arabia, on the sidelines of the 26th annual meeting of the Global Harmonization Working Party.
